KLRS Q1 2023 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$187M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$547,000

Operating Income

-$43M

Net Income

-$41M

EPS (Diluted)

$-10.15

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$244M

Total Liabilities

$51M

Stockholders' Equity

$194M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$547,000	-$846,000	+35.3%
Operating Income	-$43M	-$43M	-0.1%
Net Income	-$41M	-$44M	+6.1%